例例声辉｜不可切除局晚期NSCLC在放化疗的基石上加一剂猛药( 三 )

[2] Toma-Dasu I, Dasu A,Karlsson M. The relationship between temporal variation of hypoxia,polarographic measurements and predictions of tumour response to radiation[J].Phys Med Biol, 2004, 49(19):4463–75.
[3] Seo Y, Yan T, SchuppJE, et al. Differential radiosensitization in DNA mismatch repair-proficientand -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2′-deoxyribose[J]. Clin Cancer Res, 2004, 10(22):7520–8.
[4] Jiang XD, Dai P, QiaoY, et al. Clinical study on the recombinant human endostatin regardingimproving the blood perfusion and hypoxia of non-small-cell lung cancer[J].Clin Transl Oncol, 2012, 14(6):437–43.
[5] Meng MB, Jiang XD,Deng L, et al. Enhanced radioresponse with a novel recombinant human endostatinprotein via tumor vasculature remodeling: experimental and clinicalevidence[J]. Radiother Oncol, 2013, 106(1):130–7.
[6] Yirui Zhai, et al.HELPER study: A phase II trial of continuous infusion of endostar combined withconcurrent etoposide plus cisplatin and radiotherapy for treatment ofunresectable stage III non-small-cell lung cancer. Radiotherapy and Oncology. 2019;131:27-34.
[7] Shu-Ling Zhang ,Cheng-Bo Han , Li Sun,et al.Efficacy and safety of recombinant human endostatincombined with radiotherapy or chemoradiotherapy in patients with locallyadvanced non-small cell lung cancer: a pooled analysis[J]. Radiat Oncol, 2020Aug 24, 15(1):205.
【例例声辉｜不可切除局晚期NSCLC在放化疗的基石上加一剂猛药】*此文仅用于向医学人士提供科学信息，不代表本平台观点